PLK-3-mediated phosphorylation of BAP1 prevents diabetic retinopathy
Biochemical Pharmacology · 2024-08 · 226 · 116374
DOI: 10.1016/j.bcp.2024.116374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024-08. Verfasst von Tingyu Qin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Electronic address: fccgaoss@zzu.edu.cn. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Diabetic Retinopathy, Protein Serine-Threonine Kinases, Cell Cycle Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus, and its main clinical manifestation is retinal vascular dysfunction. DR causes blindness and is a problem with significant global health implications. However, treating DR is still challenging. In this study, we aimed to explore the role of polo-like kinase-3 (PLK-3) and the potential regulatory mechanism in DR. Sprague-Dawley rats were injected intraperitoneally with streptozotocin (STZ, 60 mg/kg) to induce a rat model of DR, and rat retinal microvascular endothelial cells (RRMECs) were treated with high glucose (HG, 25 mmol/L glucose) to develop a cell model of DR. We found that PLK-3 was significantly downregulated in the retinal tissues of STZ-induced diabetic rats and HG-induced RRMECs. Lentivirus-mediated PLK-3 overexpression alleviated the histological damages in DR rats. After HG stimulation, cell proliferation, migration, and angiogenesis in RRMECs were inhibited after PLK-3 upregulation. By using label-free proteomics, we identified 82 differentially expressed proteins downstream of PLK-3, including BRCA1-associated protein 1 (BAP1), which was significantly upregulated in PLK-3-overexpressed RRMECs compared to control cells under the HG condition. In vivo and in vitro assays indicated that the forced expression of PLK-3 increased the phosphorylation of BAP1 at serine 592 and caspase-8 expression. Detailed evidence showed that BAP1-shRNA-mediated knockdown restored the cell function in HG-treated RRMECs when PLK-3 was overexpressed. Collectively, this study shows that PLK-3 alleviates retinal vascular dysfunction in DR by inhibiting the phosphorylation of BAP1. Thus, PLK-3 may develop as a promising target for the therapy of DR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Electronic address: fccgaoss@zzu.edu.cn.
- Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zitieren
APA
Qin, T., Lv, Y., Xi, X., & Wu, Z. (2024). PLK-3-mediated phosphorylation of BAP1 prevents diabetic retinopathy. Biochemical Pharmacology, 226, 116374. https://doi.org/10.1016/j.bcp.2024.116374
Vancouver
Qin T, Lv Y, Xi X, Wu Z. PLK-3-mediated phosphorylation of BAP1 prevents diabetic retinopathy. Biochemical Pharmacology. 2024;226:116374. doi:10.1016/j.bcp.2024.116374
BibTeX
@article{Qin2024,
author = {Qin, Tingyu and Lv, Yingnan and Xi, Xiangying and Wu, Zhipeng},
title = {PLK-3-mediated phosphorylation of BAP1 prevents diabetic retinopathy},
journal = {Biochemical Pharmacology},
year = {2024},
volume = {226},
pages = {116374},
doi = {10.1016/j.bcp.2024.116374}
}
EUVIMED